StoryResearch
TRIAD enrollment surpasses 235 dogs as rapamycin trial progresses
Dog Aging ProjectTRIAD (Test of Rapamycin in Aging Dogs)
TRIAD has enrolled over 235 dogs and continues expanding toward the 580-dog target for completion by end of 2026. Participants undergo regular health assessments measuring muscle strength, cognition, immune markers and other aging-related health indicators to determine whether rapamycin extends lifespan in naturally aging companion animals.